Related Experiment Video
Updated: May 1, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges
Pratik A Lalit1, Derek J Hei, Amish N Raval
1From the Department of Medicine (P.A.L., A.N.R., T.J.K.), Molecular and Cellular Pharmacology Program (P.A.L., T.J.K.), and Stem Cell and Regenerative Medicine Center (P.A.L., D.J.H., A.N.R., T.J.K.), Waisman Biomanufacturing at University of Wisconsin, Madison (D.J.H.).
Insights
Induced pluripotent stem cells (iPSCs) offer a promising new cell source for cardiac repair after myocardial infarction. These cells can generate large quantities of cardiac cells for potential autologous or allogeneic therapies.
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Cardiovascular Research
Background:
- Coronary artery disease and myocardial infarction remain leading causes of global mortality.
- Large myocardial infarctions significantly increase the risk of heart failure and death.
- Cell-based therapies present a novel therapeutic avenue for cardiac repair.
Purpose of the Study:
- To explore the potential of induced pluripotent stem cells (iPSCs) as a cell source for cardiac repair.
- To evaluate the capacity of iPSCs to generate various cardiac cell types.
- To discuss the implications of iPSCs for both autologous and allogeneic cell-based therapies.
Main Methods:
- Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs).
- Directed differentiation of iPSCs into cardiomyocytes, smooth muscle cells, endothelial cells, and cardiac progenitors.
- Generation of clinical-grade iPSC products.
- Preclinical animal studies assessing cardiac repair with iPSC-derived cells.
Main Results:
- iPSCs can proliferate indefinitely and differentiate into multiple cardiac lineages.
- Large quantities of desired cell products can be generated, overcoming cellular senescence.
- Preclinical studies demonstrate evidence of cardiac repair using iPSC-derived cell preparations.
- Methodologies for clinical-grade iPSC production are established.
Conclusions:
- iPSCs represent a significant advancement in cell-based cardiac repair strategies.
- The potential for autologous and allogeneic therapies using iPSCs is substantial.
- Further safety studies are crucial before human clinical trials, focusing on tumorigenicity, immune rejection, and arrhythmias.
Abstract:
Coronary artery disease with associated myocardial infarction continues to be a major cause of death and morbidity around the world, despite significant advances in therapy. Patients who have large myocardial infarctions are at highest risk for progressive heart failure and death, and cell-based therapies offer new hope for these patients. A recently discovered cell source for cardiac repair has emerged as a result of a breakthrough reprogramming somatic cells to induced pluripotent stem cells (iPSCs). The iPSCs can proliferate indefinitely in culture and can differentiate into cardiac lineages, including cardiomyocytes, smooth muscle cells, endothelial cells, and cardiac progenitors. Thus, large quantities of desired cell products can be generated without being limited by cellular senescence. The iPSCs can be obtained from patients to allow autologous therapy or, alternatively, banks of human leukocyte antigen diverse iPSCs are possible for allogeneic therapy. Preclinical animal studies using a variety of cell preparations generated from iPSCs have shown evidence of cardiac repair. Methodology for the production of clinical grade products from human iPSCs is in place. Ongoing studies for the safety of various iPSC preparations with regard to the risk of tumor formation, immune rejection, induction of arrhythmias, and formation of stable cardiac grafts are needed as the field advances toward the first-in-man trials of iPSCs after myocardial infarction.
Related Concept Videos
01:06Induced Pluripotent Stem Cells
Somatic...
01:13Induced Pluripotent Stem Cells
01:13Induced Pluripotent Stem Cells
01:22iPS Cell Differentiation